On 20 April 2022, the UK Financial Conduct Authority (“FCA”) published its Policy Statement PS 22/3 on disclosures regarding diversity and inclusion targets for the boards and executive committees of UK-listed companies. These measures reflect the growing importance of  Environmental, Social and Governance (“ESG”) considerations, and have gained particular traction in the financial services sector, forming a key part of investment decisions. Indeed, July 2021 saw the FCA hone in on the “S” and “G” components on ESG with its initial consultation on D&I-related proposals.

The disclosures proposed under the policy statement (see Appendix 1) enhance market participants’ engagement with ESG, building on, and amending, the Listing Rules (“LRs”) and Disclosure Guidance and Transparency Rules (“DTRs”). Amendments to the LRs and DTRs oblige in-scope companies to annually disclose whether they meet specific diversity targets in relation to gender and ethnicity.

What are in-scope companies required to disclose?

Applicable to UK and overseas issuers with a premium or standard listing, amended LR9 and LR14 introduce ongoing listing obligations. In-scope companies must include a statement in their annual financial report setting out whether they have met specific board diversity targets, including:

  1. at least 40% of the board to be women;
  2. at least one of the senior board positions (Chair, Chief Executive Officer, Chief Financial Officer or Senior Independent Director) to be held by a woman; and
  3. at least one director to have a minority ethnic background.

The disclosures must be made by reference to a specific reference date selected by the company during the relevant accounting period.

In-scope companies are further mandated to: (1) make numerical disclosures in standardised reporting tables on board composition and senior levels of executive management by either sex or gender and ethnic identities (see Annex 2 to the LRs); (2) show how diversity policies apply to board and executive committees; and (3) clarify the elements of diversity to which such diversity policies relate.

These disclosures are to be made on a “comply or explain” basis, such that those in-scope companies that do not meet the targets will need to explain why. Where in-scope companies have members of their board or executive management situated overseas, and local law restricts the collation and publication of relevant data, they may instead explain the extent to which they are unable to make the numerical disclosures. In-scope companies must also provide an explanation of their data collation approach. Guidance as to what this explanation should entail has been issued under LR 9.8.6IG and LR 14.3.36G, highlighting the need for consistency in approach, and an overview as to the methodology or source of the data used.

The FCA has also issued additional guidance on disclosures under LR 9.8 and LR 14.3. As part of their annual reports, in-scope companies may also wish to include the following information:

  1. A brief summary of any key policies, procedures and processes that contribute to improving board and executive management diversity;
  2. Any mitigating factors or circumstances that make achieving board diversity more challenging; and
  3. Any risks the company has identified in meeting board diversity targets in the next accounting period, or any plans to improve diversity.

The FCA has also extended DTR 7.2.8AR to require in-scope companies with a diversity policy to describe their particular policy for remuneration, audit and nominations committees. Diversity policy reporting will have to take stock of wider diversity characteristics, comprising ethnicity, sexual orientation, disability and socio-economic background.

Timings

The disclosures come into force for financial years beginning on or after 1 April 2022 (with a view to be assessed after three years). This means that the new disclosures will effectively appear in in-scope companies’ annual reports from Q2 2023 onwards.

The FCA has, nonetheless, encouraged companies whose financial years began before 1 April 2022 to consider voluntarily reporting on D&I targets.  Given the prominence of ESG, coupled with existing voluntary D&I initiatives (including the FTSE Women Leaders Review; the Hampton-Alexander Review and the Parker Review), it will not be surprising to see any such voluntary reporting in an effort to attract investors in an increasingly competitive marketplace.

Practical Steps

In-scope companies should begin to take stock of their D&I initiatives and ready themselves for the new disclosure regime. They should be particularly astute to:

  1. Defining and identifying “executive management” for the purposes of understanding which individuals will be in-scope for the new rules;
  2. How relevant data will be collated, including the nature of the data collection process and associated disclosures; and
  3. Any mitigating factors or circumstances that may make achieving board diversity more challenging.
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Simon Amies Simon Amies

Simon Amies is a corporate partner with over 25 years’ experience. Clients turn to Simon to guide them on mergers and acquisitions (public and private), IPOs and other capital-raising transactions, and venture and growth capital investments.

Simon is noted for his expertise in…

Simon Amies is a corporate partner with over 25 years’ experience. Clients turn to Simon to guide them on mergers and acquisitions (public and private), IPOs and other capital-raising transactions, and venture and growth capital investments.

Simon is noted for his expertise in advising companies at all stages of their development, as well as investors and investment banks. He has particular expertise representing clients in the life sciences, technology and sustainable technology industries.

Some of Simon’s deals have included advising Renesas Electronics Corporation on its €4.9 billion recommended cash offer for Dialog Semiconductor PLC, NCC Group PLC on its $220 million acquisition of the Intellectual Property Management business of Iron Mountain Inc. and £72.6 million placing, Zeus Capital as sole bookrunner and nominated adviser to Devolver Digital, Inc. on its $950 million AIM IPO and $260 million placing, and Arecor Therapeutics plc on its AIM IPO.

Photo of Katherine Kingsbury Katherine Kingsbury

Katherine Kingsbury is a special counsel in the Corporate Practice, resident in the firm’s London office, and a core member of the firm’s Foreign Direct Investment Regulation team. Katherine regularly advises clients in relation to the UK National Security and Investment Act 2021…

Katherine Kingsbury is a special counsel in the Corporate Practice, resident in the firm’s London office, and a core member of the firm’s Foreign Direct Investment Regulation team. Katherine regularly advises clients in relation to the UK National Security and Investment Act 2021 and strategies in respect of other FDI regulatory measures in the context of global and regional transactions.

Katherine has experience advising on a broad range of corporate matters, including joint ventures, private M&A, takeovers, other significant transactions for public companies, venture capital, restructurings, and general advisory work. She has over 14 years’ experience in corporate practice, including leading knowledge management and training activities.

In addition, Katherine has particular interest in UK corporate governance and the developing ESG landscape and its application to listed companies, larger private companies, and private equity.

Summreen Mahween

Having completed a two-year training contract at the firm’s London office, Summreen Mahween is an associate in the Corporate Practice Group.

She works on a range of transactional and commercial matters, predominantly advising public and private companies on mergers and acquisitions, corporate restructurings…

Having completed a two-year training contract at the firm’s London office, Summreen Mahween is an associate in the Corporate Practice Group.

She works on a range of transactional and commercial matters, predominantly advising public and private companies on mergers and acquisitions, corporate restructurings, commercial advisory work, and general corporate governance. Her practice also focuses on capital markets transactions. Whilst her clients are wide-ranging, Summreen has a particular focus on the life sciences and technology industries.

She also has significant experience in financial services and regularly writes about, and advises on, ESG-related developments in the banking sector. Her pro bono work principally consists of advising non-profit organisations on various Business and Human Rights matters.